Abstract: The present disclosure relates to methods of analyzing the methylation level of differential DNA methylation regions (DMRs) obtained from buccal cells. Also disclosed herein are methods of analyzing methylation level of DMRs for identification and prevention of preterm birth in human subjects.

Abstract: The present disclosure relates to methods of analyzing the methylation level of differential DNA methylation regions (DMRs) obtained from buccal and blood monocyte cells. Also disclosed herein are methods of analyzing methylation level of DMRs for identification and preventative treatments of rheumatoid arthritis in human subjects.

Abstract: Provided herein are epigenetic modifications that are associated with prior exposure to chemotherapy agents. In particular, differential DNA methylation regions (DMRs) that are characteristic of, and can thus be used to identify and/or treat, a male subject who has undergone chemotherapy are provided. The DMRs are used to screen for pregnancy complications, infertility, and passage of heritable mutations to an infant.

Abstract: Provided herein are methods and kits for providing a likelihood of fertility in a subject. Further, provided herein are methods and kits for determining whether a subject responds to a fertility treatment.

Abstract: The present disclosure relates to methods of analyzing epigenetic alterations in the germline DNA of animals. More particularly, the present disclosure relates to methods of analyzing histone retention involved in epigenetic alterations as well as the identification and treatment of diseases associated with such epigenetic alterations.

Abstract: A two-step (sequential) machine learning analysis tool is provided that involves a combination of an initial active learning step followed by an imbalance class learner (ACL-ICL) protocol. This technique provides a more tightly integrated approach for a more efficient and accurate machine learning analysis. The combination of ACL and ICL work synergistically to improve the accuracy and efficiency of machine learning and can be used with any type of dataset including biological datasets.

Abstract: Provided herein are epigenetic modifications that are associated with prior exposure to chemotherapy agents. In particular, differential DNA methylation regions (DMRs) that are characteristic of, and can thus be used to identify and/or treat, a male subject who has undergone chemotherapy are provided. The DMRs are used to screen for pregnancy complications, infertility, and passage of heritable mutations to an infant.

Abstract: Provided herein are epigenetic modifications that are associated with prior exposure to chemotherapy agents. In particular, differential DNA methylation regions (DMRs) that are characteristic of, and can thus be used to identify and/or treat, a male subject who has undergone chemotherapy are provided. The DMRs are used to screen for pregnancy complications, infertility, and passage of heritable mutations to an infant.

Abstract: Provided herein are epigenetic modifications that are associated with prior exposure to chemotherapy agents. In particular, differential DNA methylation regions (DMRs) that are characteristic of, and can thus be used to identify and/or treat, a male subject who has undergone chemotherapy are provided. The DMRs are used to screen for pregnancy complications, infertility, and passage of heritable mutations to an infant.

Abstract: CpG densities and sequence motifs that are characteristic of regions of DNA associated with epimutations and control of epimutations are provided. Such regions include, within approximately 400 (or fewer) base pairs, at least one, usually two, and preferably all three of the following features: i) a CpG density of 15% or less; ii) the presence of the sequence motif ATTTGTTTTTTCTTTTnT (SEQ ID NO: 1) where n is A, T, C or G, and statistically relevant variants thereof; and iii) the presence of the sequence motif GGGGGnGGGG (SEQ ID NO: 2), where n is A, T, C or G, and statistically relevant variants thereof.

Abstract: A two-step (sequential) machine learning analysis tool is provided that involves a combination of an initial active learning step followed by an imbalance class learner (ACL-ICL) protocol. This technique provides a more tightly integrated approach for a more efficient and accurate machine learning analysis. The combination of ACL and ICL work synergistically to improve the accuracy and efficiency of machine learning and can be used with any type of dataset including biological datasets.

Abstract: The present invention provides methods for detecting epigenetic, multigenerational DNA alterations caused by toxicants such as endocrine disruptor agents in a subject. The practice of the present invention can be used to diagnose and/or treat a subject having the identified DNA alterations by developing therapeutics, to prevent or delay the onset of associated diseases and/or dysfunctions.

Abstract: The present invention relates to modified cells carrying a heterologous gene sequence encoding a protein, such as an Inhibitor of differentiation (Id) gene sequence that binds a basic helix-loop-helix (bHLH) protein to inhibit cell growth, differentiation and/or tumorigenesis of the modified cells. The modified cells are differentiated, proliferate and do not become tumorigenic when grafted into a recipient subject. Additionally, the modified cells produce a factor or factors that enhance the viability of co-grafted organs, tissues or cells. Thus, the modified cells are useful for testing agents for effects on the cells, for co-grafting with transplant organs, tissues or cells. The modified cells are also useful for enhancing the viability of thawing cells that have been cryo-preserved. In one embodiment, the modified cells are modified Sertoli cells.

Abstract: The present invention provides compositions and methods for inhibiting growth of and/or killing cancer cells. The compositions include: an inhibitor of the PI3K signal transduction pathway, and additional agents, such as Triptolide.

Abstract: The present invention relates to modified cells carrying a heterologous gene sequence encoding a protein, such as an Inhibitor of differentiation (Id) gene sequence that binds a basic helix-loop-helix (bHLH) protein to inhibit cell growth, differentiation and/or tumorigenesis of the modified cells. The modified cells are differentiated, proliferate and do not become tumorigenic when grafted into a recipient subject. Additionally, the modified cells produce a factor or factors that enhance the viability of co-grafted organs, tissues or cells. Thus, the modified cells are useful for testing agents for effects on the cells, for co-grafting with transplant organs, tissues or cells. The modified cells are also useful for enhancing the viability of thawing cells that have been cryo-preserved. In one embodiment, the modified cells are modified Sertoli cells.

Abstract: A method of assessing tumor characteristics in tissue samples by determining the copy number or expression level of genes associated with lipid metabolism, synthesis, or action is provided. Gene copy number may be assessed directly from chromosomal material or by determining the expression level of the gene in a tissue sample. The use of physical platforms comprising immobilized nucleic acid polymers to determine copy number or expression level of lipid associated genes by hybridization techniques is also provided.

Abstract: The present invention relates to non-radioactive enzymatic methods for detecting Sphingosine-1-Phosphate (S1P) in biological fluids. The present invention further relates to a method of detecting the presence of cancer in a patient by the use of these and other methods of detecting S1P in biological samples from a patient.

Abstract: The present invention relates to non-radioactive enzymatic methods for detecting Sphingosine-1-Phosphate (S1P) in biological fluids. The present invention further relates to a method of detecting the presence of cancer in a patient by the use of these and other methods of detecting S1P in biological samples from a patient.

Abstract: The present invention relates to non-radioactive enzymatic methods for detecting Sphingosine-1-Phosphate (S1P) in biological fluids. The present invention further relates to a method of detecting the presence of cancer in a patient by the use of these and other methods of detecting (S1P) in biological samples from a patient.

Abstract: The present invention identifies cDNA collections enriched in genes regulated in prostate homeostasis, prostate regression, and in genes regulated in programmed cell death. These novel cDNA collections provide cDNAs that encode proteins that are either unique to general programmed cell death or unique to prostate regression. These transcripts can be used as markers to screen, monitor and/or to diagnose diseased conditions including prostate cancer. In addition, these cDNA collections can be used in methods of designing novel therapeutic agents useful for treating prostate cancer. Methods of making these collections through subtraction hybridization are described.